Rep. Jack D. Franks

## Filed: 5/30/2007

AMENDMENT NO. and

AMENDMENT TO SENATE BILL 509
$\qquad$ . Amend Senate Bill 509, AS AMENDED, with reference to page and line numbers of House Amendment No.
on page 2, line 15, by deleting "either of"; and
on page 3, line 23, after "distributor", by inserting "or by an authorized distributor of record that purchased the product directly from the manufacturer or one of these entities"; and
on page 4, line 6, after "distributor", by inserting "or from an authorized distributor of record that purchased the product directly from the manufacturer or one of these entities"; and
on page 5, line 19, after "druq", by inserting "to a patient";
on page 5, line 23, by deleting "or"; and
on page 6, line 1, by replacing "patient." with "patient; or"; and
on page 6, immediately below line 1, by inserting the following:
"(6) an authorized distributor to a pharmacy or other persons licensed to dispense or administer the drug."; and
on page 9, line 12, after "pharmacy", by inserting ", mail order pharmacy,"; and
on page 9, lines 14 and 15, by replacing "manufacturer or to" with "manufacturer, the originating wholesale distributor, or"; and
on page 12, line 9, after "affiliates", by inserting "licensed"; and
on page 23, by replacing lines 9 through 12 with the following: "stock, to any crime under the laws of the United States or any state or territory of the United States that is a felony or a misdemeanor, of which an essential element is dishonesty, or any crime that is directly related"; and
on page 25, lines 17 and 18, by replacing "processor, and such returns or exchanges," with "processor. Returns or exchanges of prescription drugs, saleable or otherwise,"; and
by replacing line 22 on page 27 through line 20 on page 28 with the following:
"(a) Each person who is engaged in the wholesale distribution of prescription drugs, including repackagers, but excluding the original manufacturer of the finished form of the prescription drug, that leave or have ever left the normal distribution channel shall, before each wholesale distribution of the drug, provide a pedigree to the person who receives the drug. A retail pharmacy, mail order pharmacy, or chain pharmacy warehouse must comply with the requirements of this Section only if the pharmacy or chain pharmacy warehouse engages in the wholesale distribution of prescription drugs. On or before July 1, 2009, the Department shall determine a targeted implementation date for electronic track and trace pedigree technology. This targeted implementation date shall not be sooner than July 1, 2010. Beginning on the date established by the Department, pedigrees may be implemented through an approved and readily available system that electronically tracks and traces the wholesale distribution of each prescription drug starting with the sale by the manufacturer through acquisition and sale by any wholesale distributor and until final sale to a pharmacy or other authorized person

```
09500SB0509ham005 -4- LRB095 10560 RAS 37416 a
```

administering or dispensing the prescription drug. This electronic tracking system shall be deemed to be readily available only upon there being available a standardized system originating with the manufacturers and capable of being used on a wide scale across the entire pharmaceutical chain, including manufacturers, wholesale distributors, and pharmacies. Consideration must also be given to the large-scale implementation of this technology across the supply chain and the technology must be proven to have no negative impact on the safety and efficacy of the pharmaceutical product."; and
on page 31, line 9, by replacing "Section 57" with "Section 56".

